Bubs Australia Limited: 1H FY26 Financial Overview
Bubs Australia Limited (ASX: BUB) reported a 14% increase in revenue for 1H FY26, reaching AU$55.5 million, driven primarily by a 48% revenue surge in the U.S. market. The company saw robust growth in its premium natural infant formula segment, contributing to a gross profit of AU$26.6 million, though gross margin slightly decreased to 48%. Operating expenses fell by 3%, bolstered by the completion of FDA growth studies. Underlying EBITDA soared to AU$4.4 million, marking a substantial increase from AU$0.5 million in 1H FY25.
Bubs maintained a strong cash position with AU$9.9 million in cash and AU$20 million in undrawn debt facilities. Despite facing challenges such as inventory build-up to support U.S. growth and supply chain constraints, the company delivered strong results across key markets including the U.S., China, and Australia. For FY26, Bubs upgraded its outlook, forecasting a revenue range of AU$120 million to AU$125 million
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Bubs Australia Limited: 1H FY26 Financial Overview
Bubs Australia Limited (ASX: BUB) reported a 14% increase in revenue for 1H FY26, reaching AU$55.5 million, driven primarily by a 48% revenue surge in the U.S. market. The company saw robust growth in its premium natural infant formula segment, contributing to a gross profit of AU$26.6 million, though gross margin slightly decreased to 48%. Operating expenses fell by 3%, bolstered by the completion of FDA growth studies. Underlying EBITDA soared to AU$4.4 million, marking a substantial increase from AU$0.5 million in 1H FY25.
Bubs maintained a strong cash position with AU$9.9 million in cash and AU$20 million in undrawn debt facilities. Despite facing challenges such as inventory build-up to support U.S. growth and supply chain constraints, the company delivered strong results across key markets including the U.S., China, and Australia. For FY26, Bubs upgraded its outlook, forecasting a revenue range of AU$120 million to AU$125 million
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au